Synchron, a competitor to Elon Musk’s Neuralink, has completed the first brain-computer interface device implant in a human in the United States.
The first human procedure in the United States was performed at Mount Sinai Health System in New York, NY.
According to Synchron, the company has implanted a BCI in a human patient for the first time in the nation. A participant in Synchron’s COMMAND trial, which examines the efficacy and safety of BCIs for giving persons with severe paralysis hands-free device control, had the company’s Stentrode implanted by medical professionals at Mount Sinai West in New York.
In theory, technologies like Stentrode will let those who desire to email, text, and do other digital activities that other people take for granted independence.
The groundbreaking technique was carried out by clinical researchers at the Mount Sinai Health System in New York, NY, under the direction of Shahram Majidi, MD, an assistant professor of neurosurgery, neurology, and radiology at the Mount Sinai Icahn School of Medicine.
By entering the jugular vein during an endovascular operation, surgeons were able to put the implant without having to perform an invasive open-brain procedure. According to Synchron, the procedure went “extremely well,” allowing the patient to go home 48 hours later. Four individuals in an ongoing Australian trial who received their implants a year ago are still alive and well.
Before doctors may recommend Synchron’s BCIs to patients, a significant time may pass. The business gained FDA approval for human trials in July 2021, and as of the time of writing, it is still growing the COMMAND trial. Even yet, the US treatment is a big step in the direction of greater autonomy for paralyzed persons. Additionally, it’s a competitive win because Elon Musk’s Neuralink hasn’t gotten FDA approval for its own implant.
As the first FDA-approved clinical trial for a permanently implanted brain-computer interface in the US, Synchron intends to continue to expand enrollment in its COMMAND trial. According to recent long-term safety results presented at the 2022 American Academy of Neurology conference, Synchron’s SWITCH trial in Australia, which involved four patients, showed this brain-computer interface technology to be safe in four patients out to 12 months.
Frequently, Synchron has been portrayed as Musk’s Neuralink’s direct rival. Neuralink was established in 2016 in San Francisco, California. The business reported raising $205 million in a series C financing in July 2021 from investors including Google Ventures, Peter Thiel’s Founders Fund, and Sam Altman, the CEO of OpenAI.Synchron, a competitor to Elon Musk’s Neuralink, has completed the first brain-computer interface device implant in a human in the United States. The first human procedure in the United States was performed at Mount Sinai Health System in New York, NY.